Crossmark

A metabolic function of FGFR3-TACC3 gene fusions in cancer

Crossref DOI link: https://doi.org/10.1038/nature25171

Published Online: 2018-01-03

Published Print: 2018-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Frattini, Véronique

Pagnotta, Stefano M.

Tala,

Fan, Jerry J.

Russo, Marco V.

Lee, Sang Bae

Garofano, Luciano

Zhang, Jing

Shi, Peiguo

Lewis, Genevieve

Sanson, Heloise

Frederick, Vanessa

Castano, Angelica M.

Cerulo, Luigi

Rolland, Delphine C. M.

Mall, Raghvendra

Mokhtari, Karima

Elenitoba-Johnson, Kojo S. J.

Sanson, Marc

Huang, Xi

Ceccarelli, Michele

Lasorella, Anna

Iavarone, Antonio
License Information

Text and Data Mining valid from 2018-01-01
More Information

Article History

Received: 11 December 2016

Accepted: 24 November 2017

First Online: 3 January 2018

Competing interests

: A.I. and A.L. received research funds from AstraZeneca and Tahio Pharmaceutical Co., Ltd. M.S. is an investigator in two clinical trials using anti-FGFR therapies: AZD4547 (NCT02824133, funded by AstraZeneca) and TAS-120 (NCT02052778, funded by Tahio Pharmaceutical Co., Ltd). The remaining authors declare no competing financial interests.